



Letter of study termination

Bresso (Milan), 30/07/2021

RE: Clinical study NAC600-ZI-L-01-06 "Evaluation of the Clinical and Microbiological Efficacy of N-Acetilcisteine 600 mg, in Combination to Cefpodoxime Proxetile, in the Therapy of the Infections of the High Respiratory Ways in Adult Patients Clinical Study Multicentric, to Groups Parallels, Double-Blind Vs. Placebo" EudraCT Number 2007-000260-24.

Dear Sirs,

We are writing to inform you that the sponsor Zambon SpA has decided to prematurely end the NAC600-ZI-L-01-06 clinical trial of CEFODOX (5 N-acetylcysteine 600 mg, in combination with cefpodoxime proxetile). The premature end of the study is based on the sponsor's voluntary, business-related decision.

Nevertheless, Zambon remains committed to identifying effective therapies to treat the infection of the high respiratory ways in adult patients.

If you have any questions or require additional information, please contact Valentina Vaja, email: Valentina.Vaja@ZambonGroup.com.

We are asking for your kind relevant actions.

Kindest regards,

Valentina Vaja
Global Head of Scientific Operations

Zambon S.p.A.